HDM SLIT-tablet (12 SQ-HDM)

Phase 3

ALK-Abelló A/S (ALK-B.CO)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Sep '26

ALK-B.COPhase 3$8.1B

HDM SLIT-tablet (12 SQ-HDM) Phase 3 Est. Readout

HDM SLIT-tablet (12 SQ-HDM)• Allergic Rhinoconjunctivitis327

Sep 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Allergic Rhinoconjunctivitis

View Full Landscape

Drug Information

Target Indication

Allergic Rhinoconjunctivitis

Clinical Trial

NCT07060885

Last updated: 6/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ALK-B.CO

ALK-Abelló A/S

Pharmaceutical Preparations•Europe•Nasdaq Copenhagen

Related Pipeline

Sublingual allergy immunotherapy tabletPhase 3

Allergic Rhinitis Due to Dermatophagoides Farinae

AVANZ Phleum pratensePhase 3

Allergic Rhinoconjunctivitis

ALK Grass tablet - use of compliance devicePhase 3

Allergy

ALK HDM tabletPhase 3

Asthma

Grass (Phleum pratense) pollen allergen extractPhase 3

Rhinitis Allergic

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts